CLINICAL RESEARCH IN INFECTIOUS DISEASES

SAFETY SUMMARY REPORT

Prepared for the Safety Monitoring Committee

for

DMID Protocol 20-0003:

Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults

APPENDICES

02 JUNE 2020

Prepared and distributed by:
Statistical and Data Coordinating Center (SDCC)
Emmes
Rockville, Maryland

THIS COMMUNICATION IS PRIVILEGED AND CONFIDENTIAL

TABLE OF CONTENTS

APPENDIX A: Adverse Event Definitions 2
APPENDIX B: Listing of Non-Serious, Unsolicited, Moderate or Mild, or Severe Adverse Events 5
APPENDIX C1: Solicited Systemic Events 34
APPENDIX C2: Solicited Local Events 220
APPENDIX D: Attribution for Systemic Solicited Events that Contribute to Halting Criteria 355
APPENDIX E: Listing of Abnormal Clinical Laboratory Results 356
APPENDIX F: Vital Signs Listing 726
APPENDIX G1: Listing of Protocol Deviations 763
APPENDIX G2: Listing of Non-Subject Deviations 769
APPENDIX H: Listing of Pregnancies 770

APPENDIX A:
Adverse Event Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

Definition of Adverse Event (AE)

AEs means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.

Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre-existing medical condition increases, it should be recorded as an AE.

AEs can be further divided into solicited AEs and unsolicited AEs. Solicited AEs are those for which the study team will specifically query the subject whether they occurred. Unsolicited AEs are those events that the subject report occurring without being queried about the specific event.

All AEs will be assessed for severity and relationship to study intervention (see section 8.3.3 of the protocol). Reporting of all AEs, solicited and unsolicited, will occur during the period from study product administration at Day 1 through 28 days after the last vaccination. After Day 57 through the end of study on Day 394, only SAEs, MAAEs, and NOCMCs will be recorded as AEs.

All AEs, solicited and unsolicited, will be captured on the appropriate DCF. Information to be collected for AEs includes event description, date of onset, assessment of severity, relationship to study product and alternate etiology (assessed only by those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator), date of resolution, seriousness, and outcome. AEs occurring during the study-collection and reporting period will be documented appropriately regardless of relationship.

AEs will be followed to resolution or stabilization.

Severity of Adverse Events: All AEs or SAEs will be assessed for severity, according to the toxicity grading scales in the FDA "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials".

For AEs not included in the protocol-defined grading system, the following guidelines will be used to describe severity.

- Mild (Grade 1): Events that are usually transient and may require only minimal or no treatment or therapeutic intervention and generally do not interfere with the subject's usual activities of daily living.
- Moderate (Grade 2): Events that are usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research subject.

Appendix A *(continued)*
Adverse Events Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

- Severe (Grade 3): Events interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.

AEs characterized as intermittent require documentation of onset and duration of each episode. The start and stop date of each reported AE will be recorded on the appropriate DCF. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.

Relationship to Study Intervention: For each reported adverse reaction, the participating site PI or qualified designee must assess the relationship of the event to the study product using the following guidelines:

- Related – The AE is known to occur with the study intervention, there is a reasonable possibility that the study intervention caused the AE, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.
- Not Related – There is not a reasonable possibility that the administration of the study intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established.

Definition of Serious Adverse Event (SAE)

An SAE is defined in 21 CFR 312.32 as follows: "An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in any of the following outcomes:

- Death,
- a life-threatening AE,
- inpatient hospitalization or prolongation of existing hospitalization,
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions,
- or a congenital anomaly/birth defect.

Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

Appendix A *(continued)*
Adverse Events Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

"Life-threatening" refers to an AE that at occurrence represents an immediate risk of death to a subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospital admission for an elective procedure is not considered an SAE.

All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.

All SAEs will be recorded on the appropriate SAE DCF.

All SAEs will be followed through resolution or stabilization by a study clinician, licensed to make medical diagnoses and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator.

All SAEs will be reviewed and evaluated by DMID and will be sent to the SMC (for periodic review unless related) and IRB/IEC.

APPENDIX B:
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Petechiae R Elbow	14 (8)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Petechiae
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Vomiting	0 (0)	Mild	Not related	Other: brushing tongue	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Shortness of Breath With Strenuous Activity	25 (17)	Mild	Not related	Other: Deconditioning	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Abdominal Gas	4 (0)	Mild	Not related	Other medical condition or illness: food intolerance	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Flatulence

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 002**									
Systolic Hypertension	28 (8)	Mild	Not related	Other: Recent exertion	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Erythema	14 (14)	Mild	Not related	Study procedure: reaction to tape adhesive	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Erythema
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Sore Throat	1 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 002**									
Sore Throat	15 (2)	Mild	Not related	Other: environmental	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									

PRIVILEGED AND CONFIDENTIAL COMMUNICATION
PREPARED BY THE EMMES CORPORATION

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Blood Draw Site	8 (6)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Right Neck Strain	6 (2)	Mild	Not related	Other medical condition or illness: lifting weight	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Contact Dermatitis	3 (9)	Mild	Not related	Study procedure: tape adhesive reaction	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Cut On Right Index Finger	2 (2)	Mild	Not related	Other: accidental trauma	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin laceration

PRIVILEGED AND CONFIDENTIAL COMMUNICATION
PREPARED BY THE EMMES CORPORATION

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Vomiting	1 (0)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 002									
Hives On Lower Extremities	5 (1)	Mild	Related	N/A	WD- Drug withdrawn	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Urticaria
Comments: Has had episodes about once per year of hives in past, sometimes due to cat allergy and other times without known etiology. Denies noting relationship to particular activity but occurs when outdoors.									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Arm Weakness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscular weakness
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 002									
Bruise at Blood Draw Site	0 (8)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 003									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Bruise at Blood Draw Site	8 (3)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Left Palm Abrasion	5 (7)	Mild	Not related	Other: Trauma	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
Vomiting	22 (1)	Moderate	Not related	Other medical condition or illness: Sinus Headache	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Fatigue	20 (3)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Fatigue
Comments: Had mild fatigue (in retrospect) for 2 days prior to onset of sinus headache. Seasonal allergies are asymptomatic now.									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Skin Irritation Encircling Injection Site	1 (8)	Mild	Not related	Study procedure: skin irritation from band aid	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site irritation
Comments: Reddened, puffy skin the size and shape of the dot bandaid place over the injection site. No reaction in the center of the circle.									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 004									
Bruises	14 (Ongoing)	Mild	Not Related	Other - trauma from heavy weight	Not Applicable	No		Injury, poisoning and procedural complications	Contusion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 005									
Presyncope	18 (0)	Mild	Not related	Other: Sudden postural change	Not applicable	No	Recovered /resolved	Nervous system disorders	Presyncope
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 004									
Bruise at Blood Draw Site	8 (7)	Mild	Not related	Study procedure: Venipuncture trauma	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 005									
Muscle Strain	11 (3)	Mild	Not related	Other: heavy lifting	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 006									
Bruise On Right Shoulder	25 (Ongoing)	Mild	Not related	Other: trauma from carrying load	Not applicable	No		Injury, poisoning and procedural complications	Contusion
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Elevated Heart Rate	13 (14)	Mild	Not related	Other: Caffeine ingestion	Dose not changed	No	Recovered /resolved	Investigations	Heart rate increased
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Sore Throat	4 (3)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Lower Back Muscle Strain	9 (6)	Moderate	Not related	Other: Exercise	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise On Arm at Injection Site	6 (6)	Mild	Not related	Study procedure: Related to injection	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Burn On Wrist	14 (27)	Mild	Not related	Other: oven burn	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Thermal burn
Comments: 20 mm burn on left wrist from cooking									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Dizziness	1 (1)	Mild	Not related	Study procedure: phlebotomy and dehydration	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	1 (13)	Mild	Not related	Study procedure: trauma from needle	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Vasodilation On Bilateral Hands	3 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Vascular disorders	Vasodilatation
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Injection Site Itching	2 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	0 (15)	Mild	Not related	Study procedure: Vaccine injection	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Decreased Appetite	0 (7)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 003									
Itching at Injection Site	7 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Nasal Congestion	1 (0)	Mild	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 002									
R Breast Pain	20 (4)	Mild	Not related	Other: Premenstrual	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Breast pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 002									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Bradycardia	14 (Ongoing)	Mild	Not related	Other: Conditional athlete	Not applicable	No	Recovering /resolving	Cardiac disorders	Bradycardia
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
Abdominal Cramping	0 (1)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Neck Pain	2 (1)	Mild	Not related	Other: Positional stress	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Neck pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Back Muscle Strain	22 (Ongoing)	Mild	Not related	Other: positional	Not applicable	No		Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Diaphragmatic Cramping	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Diaphragmatic spasm
Comments:									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 004									
Decreased Appetite	0 (3)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 005									
Feeling of Restlessness	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Feeling jittery
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 006									
Eye Irritation	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Eye disorders	Eye irritation
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 007									
Stomach Upset	4 (0)	Mild	Not related	Other: dietary intolerance	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 008									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Itching at Injection Site	3 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 009									
Dark Stools	4 (11)	Mild	Not related	Other: Dietary change	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Faeces discoloured
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Headache	10 (0)	Moderate	Not related	Other medical condition or illness: has a baseline history of Headache	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 002									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Headache	27 (0)	Moderate	Not related	Other medical condition or illness: Tension Headaches	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Decreased Appetite	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 002									
Worsening Vaginal Itching	6 (Ongoing)	Mild	Not related	Other medical condition or illness: Vaginal Itching	Dose not changed	No	Recovering /resolving	Reproductive system and breast disorders	Vulvovaginal pruritus
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 003									
Headache	8 (12)	Mild	Not related	Other: stress	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 004									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Lip Bumps	21 (7)	Mild	Not related	Other medical condition or illness: dermatitis	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Lip disorder
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Redness at Vaccine Site	12 (3)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: Subject seen today for routine follow up visit. First noted it on 27APR2020. Size was 92mm.									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Hypertension	6 (0)	Mild	Not related	Study procedure: Failed to repeat blood pressure measurement	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Right Knee Pain	2 (0)	Mild	Not related	Other: inactivity	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Arthralgia

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 002									
Sore Throat	24 (3)	Mild	Not related	Other medical condition or illness: Viral illness	WD- Drug withdrawn	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Injection Site Redness	10 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Vaginal Spotting	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Vaginal haemorrhage
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Itching at Injection Site	7 (4)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 002**									
Bradycardia	14 (14)	Mild	Not related	Other: physical conditioning	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 005**									
Hypotension Systolic	28 (Ongoing)	Mild	Not related	Other: Decreased activity level	Dose not changed	No		Vascular disorders	Hypotension
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Muscle Strain In Neck	11 (7)	Moderate	Not related	Other: sleeping position	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle strain
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 002**									
Hypoglycemia	7 (Ongoing)	Moderate	Not related	Other: decreased PO intake	Not applicable	No	Recovering /resolving	Metabolism and nutrition disorders	Hypoglycaemia
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 001**									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Stomachache	7 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain upper
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 002									
Muscle Spasms	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle spasms
Comments: in neck and back, spasms cycled over minutes between clench and release.									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 003									
Loss of Appetite	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 002									
Vomiting	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 003									
Lightheadedness	1 (0)	Severe	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 004									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Syncope	1 (0)	Severe	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Syncope
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 005									
Bruise at Phlebotomy Site R Arm	1 (Ongoing)	Mild	Not related	Other: trauma from blood draw	Not applicable	No		General disorders and administration site conditions	Vessel puncture site bruise
Comments: This was from blood draw at urgent care visit, not a study visit, per query.									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 006									
Recurrence of Scintillating Scotomata	13 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Eye disorders	Scintillating scotoma
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 002									
Loss of Appetite	0 (2)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) AE Number: 003									
Sweating	0 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Hyperhidrosis
Comments:									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 004**									
Insomnia	7 (Ongoing)	Mild	Not related	Other: situational stress	Not applicable	No		Psychiatric disorders	Insomnia
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 005**									
Anxiety	1 (Ongoing)	Mild	Related	N/A	Not applicable	No		Psychiatric disorders	Anxiety
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 003**									
Malaise	1 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Malaise
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 004**									
Night Sweats	2 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Headache	27 (0)	Mild	Not related	Other medical condition or illness: tension headaches	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b)(6) **AE Number: 001**									
Worsening of Sciatica	5 (1)	Mild	Not related	Other: Exercise paddle boating	Dose not changed	No	Recovered /resolved	Nervous system disorders	Sciatica
Comments: Subject has pre-existing sciatica pain that occurs occasionally. Subject mentioned worsening of sciatica following paddle boating.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b)(6) **AE Number: 002**									
Exposure to Inhaled Irritants	12 (0)	Moderate	Not related	Other: exposure to onions	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Exposure via inhalation
Comments: Subject went onion picking and developed tearing and rhinorrhea. She took Benadryl with resolution of her symptoms.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b)(6) **AE Number: 001**									

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Sore Throat	1 (1)	Mild	Not related	Other medical condition or illness: SEASONAL ALLERGIES	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: She has seasonal allergies at part of her past medical history. Her sore throat felt similar to prior seasonal allergy issues that she has had due to high pollen count.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Bruise at Injection Site	1 (11)	Mild	Not related	Study procedure: Vaccine Administration	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									
Bruise at Vaccination Site	0 (4)	Mild	Not related	Study procedure: vaccination procedure	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vaccination site bruising
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) AE Number: 001									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Diastolic Hypertension	28 (Ongoing)	Mild	Not related	Other: labile blood pressure	Dose not changed	No	Recovering /resolving	Vascular disorders	Diastolic hypertension
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 001**									
No Appetite	1 (1)	Moderate	Related	N/A	Not Applicable	No	Recovered /Resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: Combined solicited systemic Symptoms kept subject from eating for > 24 hours.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Insomnia	0 (1)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Psychiatric disorders	Insomnia
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Nasal Congestion	13 (2)	Moderate	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: took pseudoephedrine once, currently mild with improved minimal residual symptoms									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Sore Throat	21 (1)	Mild	Not related	Other: Environmental Exposure	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b)(6) AE Number: 001									
Paronychia	2 (13)	Moderate	Not related	Other medical condition or illness: Bacterial Infection	Dose not changed	No	Recovered /resolved	Infections and infestations	Paronychia
Comments: Redness & Swelling that developed 25APR2020. This worsened on 26APR2020 and she presented to Urgent Care where she had an incision and drainage performed under local anesthetics (Lidocaine). She was given a dose of Ceftriaxone and discharged on Sulfamethoxazole-Trimethoprim.									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b)(6) AE Number: 002									
Maculopapular Rash	9 (Ongoing)	Moderate	Not related	Other drug: Sulfamethoxazole-Trimethoprim	WD- Drug withdrawn	No	Recovering /resolving	Skin and subcutaneous tissue disorders	Rash maculo-papular
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b)(6) AE Number: 001									
Systolic Hypertension	14 (15)	Mild	Not related	Other: labile blood pressure	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Hypoglycemia	8 (5)	Severe	Not related	Other: fasting and vigorous exercise	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Hypoglycaemia
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Vertigo	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Ear and labyrinth disorders	Vertigo
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Sunburn	4 (9)	Mild	Not related	Other: Excessive sun exposure	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Sunburn
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: [redacted] (b) (6) **AE Number: 001**									
Bilateral Ankle Swelling	2 (1)	Mild	Not related	Other: Wore a constrictive pair of new socks	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Joint swelling
Comments:									

PRIVILEGED AND CONFIDENTIAL COMMUNICATION
PREPARED BY THE EMMES CORPORATION

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Lightheadedness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Night Sweats	2 (2)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									
Anxiety	4 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Psychiatric disorders	Anxiety
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Increased Energy	0 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Energy increased
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
L Upper torso Musculoskeletal Pain	1 (12)	Moderate	Not related	Other: Bicycle accident	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain
Comments:									

Appendix B *(continued)*

Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Abrasion to L Elbow	1 (Ongoing)	Mild	Not related	Other: Bicycle accident	Dose not changed	No		Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Itching Lateral R Clavicle	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Pruritus
Comments: 5-10 minute duration									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
L Upper Arm Abrasion	0 (10)	Mild	Not related	Other: Scratched arm while doing yardwork	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Bruise at Injection Site	2 (10)	Mild	Not related	Study procedure: Needle trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Tick Bite	3 (Ongoing)	Mild	Not related	Other: Insect bite	Dose not changed	No		Injury, poisoning and procedural complications	Arthropod bite
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Dermatitis	0 (10)	Mild	Not related	Other: Reaction to adhesive on tape	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	0 (Ongoing)	Mild	Not related	Study procedure: Needle trauma from vaccine	Dose not changed	No		General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Bruise at Blood Draw Site	0 (Ongoing)	Mild	Not related	Study procedure: Needle trauma from phlebotomy	Dose not changed	No		General disorders and administration site conditions	Vessel puncture site bruise
Comments:									

PRIVILEGED AND CONFIDENTIAL COMMUNICATION
PREPARED BY THE EMMES CORPORATION

Appendix B *(continued)*
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Blood Draw Site	3 (1)	Mild	Not related	Study procedure: Needle trauma from phlebotomy	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									

APPENDIX C1:
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	Moderate	Moderate	Moderate	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Mild	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.4	None	None	None	None	None	Moderate
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Moderate	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.5	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Mild	Moderate	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.1 (Mild)	Moderate	Moderate	Moderate	None	Moderate	None
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.6	None	Mild	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	Moderate	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	None	None	None	Mild	Moderate	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Moderate	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	Mild	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	Mild	Mild	Mild	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	Mild	None	Mild	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	Mild	None	Mild	Moderate	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 9	MA	N/A				Mild		
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	None	None	Mild	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.7	Mild	Moderate	Moderate	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	Mild	Mild	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.5	None	Moderate	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.5	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	Mild
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	Mild	None	None	None	Mild
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	Mild	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Moderate	Mild	Moderate
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Moderate	Moderate	Moderate	Mild	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	Mild	None	Mild	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Mild	Moderate	Moderate	Mild	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	39.2 (Severe)	Moderate	Moderate	Moderate	Moderate	Moderate	Mild
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	Moderate	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.3	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	Moderate	Mild	Moderate	Moderate	Moderate	Moderate
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.4	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	38.4 (Mild)	Mild	Mild	Mild	None	Mild	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.2	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	Moderate	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.9	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.4	None	Moderate	Mild	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	Moderate	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.8	Mild	Moderate	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	Mild	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Moderate	Moderate	Moderate	Mild	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	Mild	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 12	MA	N/A			Mild			
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37	Mild	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	Mild	None	None	None	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	35.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	Moderate	None	None	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	Moderate	Moderate	Mild	Mild	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	Mild	None	Moderate	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	Mild	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.4	None	None	None	Moderate	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA	N/A				Mild		
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.1	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	35.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.1	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.1	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	Mild	Mild	Mild	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	Mild	Mild	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Moderate	Moderate	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	Mild	None	Mild	Mild
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.2	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.2	None	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.2	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	35.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	35.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	35.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	35.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	Moderate	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Mild	Moderate	None	Mild	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	Mild	None	Mild	Mild

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	Moderate	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.6	None	None	None	None	None	None

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Moderate	None	Mild	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	None	Mild	None	None	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	Mild	Mild	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	Mild	Moderate	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	Mild	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	Mild	None	None	Moderate	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	Mild	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.2	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	None	None	Moderate	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	Moderate	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Moderate	None	None	Mild	Moderate
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	None	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	Moderate	Moderate	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38 (Mild)	Mild	None	None	Mild	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	Mild	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b)(6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.5	None	Mild	Mild	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	Severe	Mild	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	39.6 (Severe)	Severe	Severe	Moderate	Mild	Severe	Moderate
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.4	Mild	Mild	None	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.8	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.8 (Moderate)	Severe	Severe	Moderate	Moderate	Moderate	Mild
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37	None	None	None	None	None	None
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.5	None	None	None	None	None	None
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Severe	None	Severe	None	None	Severe
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	Mild	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	Moderate	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Fever (°C)**	**Feverishness**	**Fatigue**	**Myalgia**	**Arthralgia**	**Headache**	**Nausea**
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Moderate	Mild	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Mild	Moderate	Moderate	Moderate	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	Mild	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	Mild	Moderate	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.7	None	Mild	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	Mild	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (ºC)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	Mild	Mild	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	Mild	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	37.2	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.2	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	37.3	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.2	None	None	Mild	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	Mild	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.2	None	None	Mild	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 14	MA	N/A			Mild			
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.5	None	Mild	Mild	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	Mild	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 *(continued)*
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.
Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)
See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

APPENDIX C2:
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
[redacted] (b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	Mild	0	1
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	2
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	2
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Moderate	0	75 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Moderate	0	78 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	Mild	0	36 (Mild)
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	Mild	0	26 (Mild)
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Moderate	0	65 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Moderate	0	76 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	23
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	Mild	0	35 (Mild)
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	20
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	15
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	Mild	None	1	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	Mild	None	1	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	Mild	None	3	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	Mild	None	3	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	Mild	None	3	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA	-	Mild	-	2	-
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	1	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	1

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	10
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	8
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	3
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	Mild	0	2
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	3	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	Mild	None	2	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	Mild	None	2	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	3	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	Mild	None	65 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	65 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	40 (Mild)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	40 (Mild)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	50 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	Mild	None	25 (Mild)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	Mild	0	15
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	20
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	5

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	Mild	0	1
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	Mild	Mild	Mild	2	3
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Moderate	None	Mild	0	50 (Moderate)
[redacted]	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	3
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	2
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	Mild	Mild	5	30 (Mild)
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	Mild	Mild	60 (Moderate)	45 (Mild)
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	35 (Mild)	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	Mild	40 (Mild)	40 (Mild)
	100 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	-	Mild	Mild	110 (Severe)	40 (Mild)
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	115 (Severe)	90 (Moderate)

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	Mild	None	60 (Moderate)	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	Mild	None	60 (Moderate)	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	Not Done	Not Done	Not Done		
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	Mild	None	20	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	None	20	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	7
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	30 (Mild)
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Mild	0	20
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	Mild	0	30 (Mild)
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Mild	0	1
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	1
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	None	50 (Moderate)	50 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	-	Mild	-	105 (Severe)	105 (Severe)
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	Mild	Mild	10	60 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	Mild	75 (Moderate)	60 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	105 (Severe)	25 (Mild)

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	60 (Moderate)	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	Not Done	Not Done	Not Done	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	Mild	None	2	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
[redacted]	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	Mild	None	20	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	Mild	None	20	20
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	**Vaccination Group**	**Dose Number**	**Post Dose Day**	**Assessment***	**Pain**	**Erythema/redness**	**Induration/swelling**	**Erythema/redness measurement (mm)**	**Induration/swelling (mm)**
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
[redacted]	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 *(continued)*
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.
Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)
See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

APPENDIX D:
Attribution for Systemic Solicited Events that Contribute to Halting Criteria

Subject ID	Vaccination Group	Systemic Reaction	Dose Number	Post-Dose Day	Severity	Attributed to Alternate Etiology?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	Fever	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	1	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Headache	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Fever	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Myalgia	02	2	SEVERE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	Nausea	02	2	SEVERE	No

APPENDIX E:
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy procedure	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	PT (seconds)	11.8 (Mild)	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-14	PT (seconds)	10.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Platelets (10~{super 3}/uL)	190	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Platelets (10~{super 3}/uL)	182	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Platelets (10~{super 3}/uL)	197	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Platelets (10~{super 3}/uL)	212	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	WBC (10~{super 3}/uL)	3.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-15	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alkaline Phosphatase (U/L)	85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PT (seconds)	10.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PTT (seconds)	32	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Platelets (10~{super 3}/uL)	332	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Platelets (10~{super 3}/uL)	334	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Platelets (10~{super 3}/uL)	358	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Platelets (10~{super 3}/uL)	343	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Platelets (10~{super 3}/uL)	366	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Platelets (10~{super 3}/uL)	201	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Platelets (10~{super 3}/uL)	217	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Platelets (10~{super 3}/uL)	206	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Platelets (10~{super 3}/uL)	238	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	WBC (10~{super 3}/uL)	7.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Hemoglobin (g/dL)	15.6 (Mild)	NOT RELATED	Due to phlebotomy (study procedure)	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	PT (seconds)	10.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Platelets (10~{super 3}/uL)	163	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Platelets (10~{super 3}/uL)	185	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Platelets (10~{super 3}/uL)	195	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Platelets (10~{super 3}/uL)	170	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Platelets (10~{super 3}/uL)	162	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Total Bilirubin (mg/dL)	1.5 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-2	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Total Bilirubin (mg/dL)	1.4 (Mild)	NOT RELATED	Grade 1 Similar to baseline bilirubin	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	57	55	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Platelets (10~{super 3}/uL)	215	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Platelets (10~{super 3}/uL)	206	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Platelets (10~{super 3}/uL)	219	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Platelets (10~{super 3}/uL)	237	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Platelets (10~{super 3}/uL)	222	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Platelets (10~{super 3}/uL)	226	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Platelets (10~{super 3}/uL)	252	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Platelets (10~{super 3}/uL)	227	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Platelets (10~{super 3}/uL)	231	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Serum Lipase (U/L)	78.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Serum Lipase (U/L)	70.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	57	56	Serum Lipase (U/L)	77.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	WBC (10~{super 3}/uL)	3.2 (Mild)	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	WBC (10~{super 3}/uL)	2.8 (Mild)	NOT RELATED	Grade I - similar to Grade I that was present prior to receipt of vaccine	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	WBC (10~{super 3}/uL)	3.0 (Mild)	NOT RELATED	Grade 1 Similar to her baseline	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	57	56	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Creatinine (mg/dL)	1.15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	Due to study - phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Hemoglobin (g/dL)	15.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	PT (seconds)	10.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Platelets (10~{super 3}/uL)	175	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Platelets (10~{super 3}/uL)	168	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Platelets (10~{super 3}/uL)	174	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Platelets (10~{super 3}/uL)	170	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Platelets (10~{super 3}/uL)	189	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Grade 1 due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	PTT (seconds)	29	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Platelets (10~{super 3}/uL)	291	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Platelets (10~{super 3}/uL)	275	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Platelets (10~{super 3}/uL)	282	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Platelets (10~{super 3}/uL)	281	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Platelets (10~{super 3}/uL)	318	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Serum Lipase (U/L)	64.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-19	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Serum Lipase (U/L)	59.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Hemoglobin (g/dL)	16.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Hemoglobin (g/dL)	14.7 (Moderate)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	PTT (seconds)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Platelets (10~{super 3}/uL)	266	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Platelets (10~{super 3}/uL)	266	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Platelets (10~{super 3}/uL)	241	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Platelets (10~{super 3}/uL)	253	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Serum Lipase (U/L)	112.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	PTT (seconds)	36 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-4	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Platelets (10~{super 3}/uL)	304	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Platelets (10~{super 3}/uL)	283	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Platelets (10~{super 3}/uL)	277	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-4	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	WBC (10~{super 3}/uL)	8.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	WBC (10~{super 3}/uL)	6.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	69	29	28	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6)	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	PT (seconds)	11.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Platelets (10~{super 3}/uL)	228	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Platelets (10~{super 3}/uL)	217	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Platelets (10~{super 3}/uL)	203	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Platelets (10~{super 3}/uL)	199	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Platelets (10~{super 3}/uL)	181	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Platelets (10~{super 3}/uL)	196	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Platelets (10~{super 3}/uL)	209	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Platelets (10~{super 3}/uL)	192	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Platelets (10~{super 3}/uL)	189	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Platelets (10~{super 3}/uL)	185	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alkaline Phosphatase (U/L)	103	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Alkaline Phosphatase (U/L)	104	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Alkaline Phosphatase (U/L)	102	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Platelets (10~{super 3}/uL)	320	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Platelets (10~{super 3}/uL)	332	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Platelets (10~{super 3}/uL)	337	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Platelets (10~{super 3}/uL)	352	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	WBC (10~{super 3}/uL)	8.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	WBC (10~{super 3}/uL)	8.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	WBC (10~{super 3}/uL)	9.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	WBC (10~{super 3}/uL)	8.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Hemoglobin (g/dL)	13.1 (Moderate)	RELATED	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Platelets (10~{super 3}/uL)	206	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Platelets (10~{super 3}/uL)	217	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	PTT (seconds)	21	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Platelets (10~{super 3}/uL)	216	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Platelets (10~{super 3}/uL)	199	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Platelets (10~{super 3}/uL)	216	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Platelets (10~{super 3}/uL)	202	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Serum Lipase (U/L)	57.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy	NA-NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	PTT (seconds)	31	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Platelets (10~{super 3}/uL)	371	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Platelets (10~{super 3}/uL)	355	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Platelets (10~{super 3}/uL)	370	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Platelets (10~{super 3}/uL)	352	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Total Bilirubin (U/L)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	WBC (10~{super 3}/uL)	7.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	WBC (10~{super 3}/uL)	7.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Creatinine (mg/dL)	1.19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Platelets (10~{super 3}/uL)	256	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Platelets (10~{super 3}/uL)	250	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Serum Lipase (U/L)	65.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	WBC (10~{super 3}/uL)	7.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Platelets (10~{super 3}/uL)	361	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Platelets (10~{super 3}/uL)	395	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Platelets (10~{super 3}/uL)	388	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Platelets (10~{super 3}/uL)	350	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b)(6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Platelets (10~{super 3}/uL)	350	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Platelets (10~{super 3}/uL)	352	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Platelets (10~{super 3}/uL)	346	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Platelets (10~{super 3}/uL)	358	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Serum Lipase (U/L)	42.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Alanine Aminotransferase (U/L)	52 (Mild)	NOT RELATED	Related to Alcohol	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alanine Aminotransferase (U/L)	37	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	PT (seconds)	9.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	PTT (seconds)	33	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Platelets (10~{super 3}/uL)	367	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Platelets (10~{super 3}/uL)	321	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Platelets (10~{super 3}/uL)	379	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Platelets (10~{super 3}/uL)	367	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Platelets (10~{super 3}/uL)	345	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Alanine Aminotransferase (U/L)	88 (Mild)	NOT RELATED	subject confirmed alcohol use	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Aspartate Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Creatinine (mg/dL)	1.18	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Creatinine (mg/dL)	1.20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Creatinine (mg/dL)	1.14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Creatinine (mg/dL)	1.26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Hemoglobin (g/dL)	13.1 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Platelets (10~{super 3}/uL)	359	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Platelets (10~{super 3}/uL)	321	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Platelets (10~{super 3}/uL)	328	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Platelets (10~{super 3}/uL)	302	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Platelets (10~{super 3}/uL)	348	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	WBC (10~{super 3}/uL)	8.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	WBC (10~{super 3}/uL)	7.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	WBC (10~{super 3}/uL)	7.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	WBC (10~{super 3}/uL)	6.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	WBC (10~{super 3}/uL)	6.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Platelets (10~{super 3}/uL)	265	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Platelets (10~{super 3}/uL)	245	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Platelets (10~{super 3}/uL)	260	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Platelets (10~{super 3}/uL)	235	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Normal variation	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	normal lab variation	NA- NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	PT (seconds)	11.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Platelets (10~{super 3}/uL)	247	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Platelets (10~{super 3}/uL)	222	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Platelets (10~{super 3}/uL)	217	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Platelets (10~{super 3}/uL)	211	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Platelets (10~{super 3}/uL)	249	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	PT (seconds)	10.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	PTT (seconds)	29	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Platelets (10~{super 3}/uL)	354	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Platelets (10~{super 3}/uL)	373	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Platelets (10~{super 3}/uL)	420	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Platelets (10~{super 3}/uL)	415	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Platelets (10~{super 3}/uL)	407	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	related to study procedure	NA- NOT APPLICABLE	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Hemoglobin (g/dL)	13.6 (Mild)	-	-	-	-
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	PT (seconds)	10.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	PTT (seconds)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Platelets (10~{super 3}/uL)	211	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Platelets (10~{super 3}/uL)	187	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Platelets (10~{super 3}/uL)	186	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Platelets (10~{super 3}/uL)	195	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Platelets (10~{super 3}/uL)	199	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	WBC (10~{super 3}/uL)	8.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	WBC (10~{super 3}/uL)	7.9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Alanine Aminotransferase (U/L)	6	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Alanine Aminotransferase (U/L)	6	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Aspartate Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Hemoglobin (g/dL)	12.2 (Moderate)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	PTT (seconds)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Platelets (10~{super 3}/uL)	270	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Platelets (10~{super 3}/uL)	278	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Platelets (10~{super 3}/uL)	285	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Platelets (10~{super 3}/uL)	273	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Platelets (10~{super 3}/uL)	238	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	WBC (10~{super 3}/uL)	8.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	WBC (10~{super 3}/uL)	7.2	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	WBC (10~{super 3}/uL)	8.1	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	WBC (10~{super 3}/uL)	7.6	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	related to study blood draws	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	PT (seconds)	9.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Platelets (10~{super 3}/uL)	332	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Platelets (10~{super 3}/uL)	324	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Platelets (10~{super 3}/uL)	343	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Platelets (10~{super 3}/uL)	308	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Platelets (10~{super 3}/uL)	320	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	WBC (10~{super 3}/uL)	7.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	WBC (10~{super 3}/uL)	8.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	study procedure (phlebotomy)	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	PTT (seconds)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Platelets (10~{super 3}/uL)	173	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Platelets (10~{super 3}/uL)	180	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Platelets (10~{super 3}/uL)	159	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Platelets (10~{super 3}/uL)	180	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Platelets (10~{super 3}/uL)	188	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Serum Lipase (U/L)	67.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Hemoglobin (g/dL)	15.0 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Hemoglobin (g/dL)	15.4 (Mild)	.	.	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	PT (seconds)	10.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Platelets (10~{super 3}/uL)	232	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Platelets (10~{super 3}/uL)	226	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Platelets (10~{super 3}/uL)	215	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Platelets (10~{super 3}/uL)	217	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Alkaline Phosphatase (U/L)	80	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Normal variation or phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	PTT (seconds)	27	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Platelets (10~{super 3}/uL)	279	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Platelets (10~{super 3}/uL)	278	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Platelets (10~{super 3}/uL)	269	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Platelets (10~{super 3}/uL)	278	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	-1	-5	WBC (10~{super 3}/uL)	7.1	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	1	1	WBC (10~{super 3}/uL)	6.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	8	8	WBC (10~{super 3}/uL)	8.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	71	29	29	WBC (10~{super 3}/uL)	7.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Hemoglobin (g/dL)	16.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Hemoglobin (g/dL)	14.8 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Hemoglobin (g/dL)	14.1 (Severe)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Platelets (10~{super 3}/uL)	280	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Platelets (10~{super 3}/uL)	312	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Platelets (10~{super 3}/uL)	273	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Platelets (10~{super 3}/uL)	271	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	WBC (10~{super 3}/uL)	6.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Hemoglobin (g/dL)	12.3 (Mild)	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Platelets (10~{super 3}/uL)	310	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Platelets (10~{super 3}/uL)	320	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Platelets (10~{super 3}/uL)	316	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Platelets (10~{super 3}/uL)	287	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	WBC (10~{super 3}/uL)	8.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	WBC (10~{super 3}/uL)	7.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Hemoglobin (g/dL)	13.6 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Platelets (10~{super 3}/uL)	167	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Platelets (10~{super 3}/uL)	167	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Platelets (10~{super 3}/uL)	159	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Platelets (10~{super 3}/uL)	163	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-4	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Alkaline Phosphatase (U/L)	37	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	PT (seconds)	10.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	PTT (seconds)	29	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Platelets (10~{super 3}/uL)	287	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Platelets (10~{super 3}/uL)	284	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Platelets (10~{super 3}/uL)	287	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Platelets (10~{super 3}/uL)	283	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Aspartate Aminotransferase (U/L)	54 (Mild)	NOT RELATED	alcohol consumption	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Platelets (10~{super 3}/uL)	219	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Platelets (10~{super 3}/uL)	240	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Platelets (10~{super 3}/uL)	222	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Alanine Aminotransferase (U/L)	46	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Hemoglobin (g/dL)	16.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Platelets (10~{super 3}/uL)	264	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Platelets (10~{super 3}/uL)	186	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Platelets (10~{super 3}/uL)	225	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Platelets (10~{super 3}/uL)	183	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Platelets (10~{super 3}/uL)	193	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	WBC (10~{super 3}/uL)	7.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Platelets (10~{super 3}/uL)	269	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Platelets (10~{super 3}/uL)	270	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Platelets (10~{super 3}/uL)	282	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Platelets (10~{super 3}/uL)	290	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Platelets (10~{super 3}/uL)	287	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	WBC (10~{super 3}/uL)	3.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alkaline Phosphatase (U/L)	34	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Alkaline Phosphatase (U/L)	33	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Hemoglobin (g/dL)	11.2 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	PTT (seconds)	27	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Platelets (10~{super 3}/uL)	235	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Platelets (10~{super 3}/uL)	224	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Platelets (10~{super 3}/uL)	231	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Platelets (10~{super 3}/uL)	231	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Platelets (10~{super 3}/uL)	274	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Aspartate Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	PT (seconds)	9.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Platelets (10~{super 3}/uL)	278	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Platelets (10~{super 3}/uL)	317	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Platelets (10~{super 3}/uL)	319	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Platelets (10~{super 3}/uL)	295	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Platelets (10~{super 3}/uL)	295	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	WBC (10~{super 3}/uL)	8.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	WBC (10~{super 3}/uL)	3.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	WBC (10~{super 3}/uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Platelets (10~{super 3}/uL)	248	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Platelets (10~{super 3}/uL)	245	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Platelets (10~{super 3}/uL)	251	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Platelets (10~{super 3}/uL)	235	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Platelets (10~{super 3}/uL)	272	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	-1	-8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	1	1	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	8	7	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	29	29	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	33	36	35	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Hemoglobin (g/dL)	11.1 (Mild)	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Hemoglobin (g/dL)	10.5 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Hemoglobin (g/dL)	10.3 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	PT (seconds)	9.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	PTT (seconds)	27	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Platelets (10~{super 3}/uL)	307	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Platelets (10~{super 3}/uL)	254	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Platelets (10~{super 3}/uL)	251	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Platelets (10~{super 3}/uL)	243	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Platelets (10~{super 3}/uL)	297	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-8	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	WBC (10~{super 3}/uL)	3.4 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	7	WBC (10~{super 3}/uL)	3.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	29	WBC (10~{super 3}/uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	37	WBC (10~{super 3}/uL)	3.8	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Hemoglobin (g/dL)	12.9 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Platelets (10~{super 3}/uL)	245	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Platelets (10~{super 3}/uL)	240	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Platelets (10~{super 3}/uL)	217	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Platelets (10~{super 3}/uL)	272	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Platelets (10~{super 3}/uL)	272	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	-1	-15	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	1	1	WBC (10~{super 3}/uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	8	9	WBC (10~{super 3}/uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	44	29	29	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	44	36	37	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Alanine Aminotransferase (U/L)	66 (Mild)	NOT RELATED	increased alcohol night before	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Alanine Aminotransferase (U/L)	42	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Creatinine (mg/dL)	1.22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	PTT (seconds)	32	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Platelets (10~{super 3}/uL)	219	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Platelets (10~{super 3}/uL)	219	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Platelets (10~{super 3}/uL)	232	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Platelets (10~{super 3}/uL)	227	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Serum Lipase (U/L)	8.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	-1	-15	WBC (10~{super 3}/uL)	8.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	37	1	1	WBC (10~{super 3}/uL)	8.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	8	9	WBC (10~{super 3}/uL)	8.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	29	29	WBC (10~{super 3}/uL)	8.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	37	36	37	WBC (10~{super 3}/uL)	7.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Hemoglobin (g/dL)	11.5 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	57	58	Hemoglobin (g/dL)	11.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	PT (seconds)	10.1	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Platelets (10~{super 3}/uL)	302	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Platelets (10~{super 3}/uL)	290	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Platelets (10~{super 3}/uL)	247	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Platelets (10~{super 3}/uL)	234	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Platelets (10~{super 3}/uL)	260	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	-1	-7	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	1	1	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	8	7	WBC (10~{super 3}/uL)	3.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	29	29	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	53	36	37	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Study procedure	NA-NOT APPLICABLE	No
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	PT (seconds)	9.9	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	PTT (seconds)	28	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Platelets (10~{super 3}/uL)	240	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Platelets (10~{super 3}/uL)	269	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Platelets (10~{super 3}/uL)	289	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Platelets (10~{super 3}/uL)	246	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Platelets (10~{super 3}/uL)	280	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-7	WBC (10~{super 3}/uL)	7.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	WBC (10~{super 3}/uL)	7.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	7	WBC (10~{super 3}/uL)	7.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	WBC (10~{super 3}/uL)	7.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	WBC (10~{super 3}/uL)	6.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Platelets (10~{super 3}/uL)	280	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Platelets (10~{super 3}/uL)	253	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Platelets (10~{super 3}/uL)	231	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Platelets (10~{super 3}/uL)	255	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-14	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	WBC (10~{super 3}/uL)	2.9 (Mild)	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	9	WBC (10~{super 3}/uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	WBC (10~{super 3}/uL)	2.8 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	37	WBC (10~{super 3}/uL)	2.7 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Platelets (10~{super 3}/uL)	313	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Platelets (10~{super 3}/uL)	264	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Platelets (10~{super 3}/uL)	227	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Platelets (10~{super 3}/uL)	273	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Platelets (10~{super 3}/uL)	274	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-12	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	33	8	9	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	33	36	37	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Alanine Aminotransferase (U/L)	48	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Platelets (10~{super 3}/uL)	298	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Platelets (10~{super 3}/uL)	285	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Platelets (10~{super 3}/uL)	311	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Platelets (10~{super 3}/uL)	309	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Platelets (10~{super 3}/uL)	310	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Serum Lipase (U/L)	16.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	-1	-12	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	1	1	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	8	9	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	29	29	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	41	36	36	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Alanine Aminotransferase (U/L)	45	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Aspartate Aminotransferase (U/L)	45 (Mild)	NOT RELATED	Alcohol intake	NA- NOT APPLICABLE	No
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Platelets (10~{super 3}/uL)	286	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Platelets (10~{super 3}/uL)	248	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Platelets (10~{super 3}/uL)	251	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Platelets (10~{super 3}/uL)	249	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Platelets (10~{super 3}/uL)	257	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	-1	-11	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	53	1	1	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	8	9	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	29	29	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	53	36	37	WBC (10~{super 3}/uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Creatinine (mg/dL)	0.52	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Creatinine (mg/dL)	0.59	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Creatinine (mg/dL)	0.53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Platelets (10~{super 3}/uL)	241	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Platelets (10~{super 3}/uL)	249	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Platelets (10~{super 3}/uL)	293	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Platelets (10~{super 3}/uL)	224	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Platelets (10~{super 3}/uL)	257	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-11	WBC (10~{super 3}/uL)	5.2	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	9	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	29	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	37	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Aspartate Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Hemoglobin (g/dL)	14.7 (Moderate)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Hemoglobin (g/dL)	16.1 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Hemoglobin (g/dL)	16.2 (Mild)	.	.	.	.
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	PTT (seconds)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Platelets (10~{super 3}/uL)	251	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Platelets (10~{super 3}/uL)	223	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Platelets (10~{super 3}/uL)	252	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Platelets (10~{super 3}/uL)	195	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Platelets (10~{super 3}/uL)	269	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-26	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	8	8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	29	28	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Hemoglobin (g/dL)	13.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	PT (seconds)	10.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Platelets (10~{super 3}/uL)	172	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Platelets (10~{super 3}/uL)	167	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Platelets (10~{super 3}/uL)	148	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Platelets (10~{super 3}/uL)	163	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	-1	-11	WBC (10~{super 3}/uL)	7.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	8	9	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	31	29	29	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	31	36	37	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	PT (seconds)	10.8	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	PTT (seconds)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Platelets (10~{super 3}/uL)	327	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Platelets (10~{super 3}/uL)	312	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Platelets (10~{super 3}/uL)	324	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Platelets (10~{super 3}/uL)	302	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Platelets (10~{super 3}/uL)	335	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	Total Bilirubin (mg/dL)	1.6 (Mild)	NOT RELATED	suspected gilberts	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	Total Bilirubin (mg/dL)	2.1 (Moderate)	NOT RELATED	suspected Gilberts	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	Total Bilirubin (mg/dL)	1.8 (Mild)	NOT RELATED	Other	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	27	-1	-8	WBC (10~{super 3}/uL)	8.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	1	1	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	MALE	27	8	9	WBC (10~{super 3}/uL)	6.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	29	29	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	27	36	37	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Alkaline Phosphatase (U/L)	31	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Platelets (10~{super 3}/uL)	234	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Platelets (10~{super 3}/uL)	209	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Platelets (10~{super 3}/uL)	227	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Platelets (10~{super 3}/uL)	219	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	-1	-22	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	1	1	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	8	8	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	29	28	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	29	36	35	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Hemoglobin (g/dL)	14.8 (Mild)	.	.	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	PT (seconds)	10.6	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	PTT (seconds)	25	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Platelets (10~{super 3}/uL)	241	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Platelets (10~{super 3}/uL)	266	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Platelets (10~{super 3}/uL)	265	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Platelets (10~{super 3}/uL)	287	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Platelets (10~{super 3}/uL)	284	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Serum Lipase (U/L)	58.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	Total Bilirubin (mg/dL)	1.5 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	-1	-26	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	1	1	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	8	8	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	29	29	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	33	36	36	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Hemoglobin (g/dL)	12.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	PT (seconds)	9.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	PTT (seconds)	27	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Platelets (10~{super 3}/uL)	317	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Platelets (10~{super 3}/uL)	278	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Platelets (10~{super 3}/uL)	281	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Platelets (10~{super 3}/uL)	301	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	-1	-21	WBC (10~{super 3}/uL)	7.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	1	1	WBC (10~{super 3}/uL)	7.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	8	8	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	19	36	35	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Alkaline Phosphatase (U/L)	122	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Alkaline Phosphatase (U/L)	106	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Alkaline Phosphatase (U/L)	93	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Hemoglobin (g/dL)	16.2 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Platelets (10~{super 3}/uL)	199	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Platelets (10~{super 3}/uL)	207	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Platelets (10~{super 3}/uL)	190	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Platelets (10~{super 3}/uL)	174	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Platelets (10~{super 3}/uL)	190	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	-1	-20	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	1	1	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	29	8	8	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	29	28	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	29	36	35	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	PT (seconds)	10.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	PTT (seconds)	27	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Platelets (10~{super 3}/uL)	242	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Platelets (10~{super 3}/uL)	245	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Platelets (10~{super 3}/uL)	248	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Platelets (10~{super 3}/uL)	216	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Platelets (10~{super 3}/uL)	261	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-25	WBC (10~{super 3}/uL)	3.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	WBC (10~{super 3}/uL)	3.4 (Mild)	RELATED	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	29	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	37	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	PTT (seconds)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Platelets (10~{super 3}/uL)	193	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Platelets (10~{super 3}/uL)	210	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Platelets (10~{super 3}/uL)	245	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	-1	-24	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	1	1	WBC (10~{super 3}/uL)	7.4	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	8	8	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	29	29	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	MALE	23	36	37	WBC (10~{super 3}/uL)	6.7	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Hemoglobin (g/dL)	11.4 (Mild)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotom y	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotom y	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	PT (seconds)	10.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	PTT (seconds)	28	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Platelets (10~{super 3}/uL)	298	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Platelets (10~{super 3}/uL)	243	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Platelets (10~{super 3}/uL)	247	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Platelets (10~{super 3}/uL)	210	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Platelets (10~{super 3}/uL)	255	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	-1	-24	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	1	1	WBC (10~{super 3}/uL)	4.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	8	8	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	29	29	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	30	36	37	WBC (10~{super 3}/uL)	3.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	PTT (seconds)	26	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Platelets (10~{super 3}/uL)	189	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Platelets (10~{super 3}/uL)	202	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Platelets (10~{super 3}/uL)	193	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Platelets (10~{super 3}/uL)	216	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Platelets (10~{super 3}/uL)	221	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	-1	-21	WBC (10~{super 3}/uL)	7.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	8	8	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	29	29	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	31	36	37	WBC (10~{super 3}/uL)	6.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Creatinine (mg/dL)	1.21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Platelets (10~{super 3}/uL)	185	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Platelets (10~{super 3}/uL)	210	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	74	-1	-17	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	74	8	9	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	PTT (seconds)	27	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Platelets (10~{super 3}/uL)	260	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Platelets (10~{super 3}/uL)	250	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Platelets (10~{super 3}/uL)	267	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-17	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	WBC (10~{super 3}/uL)	3.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Platelets (10~{super 3}/uL)	203	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	211	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	230	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	67.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	PTT (seconds)	30	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Platelets (10~{super 3}/uL)	276	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	273	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	282	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-17	WBC (10~{super 3}/uL)	7.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	6.8	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alkaline Phosphatase (U/L)	95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PT (seconds)	10.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Platelets (10~{super 3}/uL)	207	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	228	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	7.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Hemoglobin (g/dL)	13.1 (Mild)	.	.	.	.
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	PT (seconds)	9.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Platelets (10~{super 3}/uL)	442	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-15	Platelets (10~{super 3}/uL)	389	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Platelets (10~{super 3}/uL)	362	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Platelets (10~{super 3}/uL)	363	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	-1	-22	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	1	1	WBC (10~{super 3}/uL)	5.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	75	8	9	WBC (10~{super 3}/uL)	6.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Alkaline Phosphatase (U/L)	92	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Platelets (10~{super 3}/uL)	151	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	153	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Platelets (10~{super 3}/uL)	188	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-14	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	3.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	72	8	9	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	PTT (seconds)	31	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Platelets (10~{super 3}/uL)	201	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Platelets (10~{super 3}/uL)	165	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Platelets (10~{super 3}/uL)	176	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-14	WBC (10~{super 3}/uL)	4.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Hemoglobin (g/dL)	11.9 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	12.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	PT (seconds)	10.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Platelets (10~{super 3}/uL)	219	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Platelets (10~{super 3}/uL)	191	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Platelets (10~{super 3}/uL)	200	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Serum Lipase (U/L)	67.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-15	WBC (10~{super 3}/uL)	5.1	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	WBC (10~{super 3}/uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	WBC (10~{super 3}/uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	PT (seconds)	10.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	PTT (seconds)	26	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Platelets (10~{super 3}/uL)	366	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Platelets (10~{super 3}/uL)	333	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Platelets (10~{super 3}/uL)	354	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
[redacted] (b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-15	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	WBC (10~{super 3}/uL)	4.9	N/A	N/A	N/A	N/A
[redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	73	8	9	WBC (10~{super 3}/uL)	6.0	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Creatinine (mg/dL)	0.55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	12.0 (Mild)	.	.	.	.
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Platelets (10~{super 3}/uL)	189	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-21	WBC (10~{super 3}/uL)	3.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-15	WBC (10~{super 3}/uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	WBC (10~{super 3}/uL)	3.1 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	WBC (10~{super 3}/uL)	3.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Hemoglobin (g/dL)	13.0 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Platelets (10~{super 3}/uL)	204	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Platelets (10~{super 3}/uL)	196	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Platelets (10~{super 3}/uL)	208	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-13	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	WBC (10~{super 3}/uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (≥71 years)	MALE	71	8	9	WBC (10~{super 3}/uL)	6.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Hemoglobin (g/dL)	12.7 (Mild)	.	.	.	.
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	PTT (seconds)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Platelets (10~{super 3}/uL)	171	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Platelets (10~{super 3}/uL)	187	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Platelets (10~{super 3}/uL)	183	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-13	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	9	WBC (10~{super 3}/uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	PT (seconds)	9.6	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Platelets (10~{super 3}/uL)	356	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Platelets (10~{super 3}/uL)	369	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Platelets (10~{super 3}/uL)	357	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-19	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	WBC (10~{super 3}/uL)	7.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	PT (seconds)	10.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Platelets (10~{super 3}/uL)	195	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Platelets (10~{super 3}/uL)	186	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Platelets (10~{super 3}/uL)	194	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	-1	-20	WBC (10~{super 3}/uL)	5.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	1	1	WBC (10~{super 3}/uL)	4.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	73	8	8	WBC (10~{super 3}/uL)	5.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Hemoglobin (g/dL)	11.0 (Mild)	.	.	.	.
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Platelets (10~{super 3}/uL)	242	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Platelets (10~{super 3}/uL)	257	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Platelets (10~{super 3}/uL)	234	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	-1	-20	WBC (10~{super 3}/uL)	5.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	1	1	WBC (10~{super 3}/uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	72	8	8	WBC (10~{super 3}/uL)	6.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	PT (seconds)	9.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Platelets (10~{super 3}/uL)	281	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Platelets (10~{super 3}/uL)	318	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Platelets (10~{super 3}/uL)	303	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	Total Bilirubin (mg/dL)	1.4 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	-1	-19	WBC (10~{super 3}/uL)	4.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	1	1	WBC (10~{super 3}/uL)	4.5	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	FEMALE	73	8	8	WBC (10~{super 3}/uL)	4.2	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
[redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Platelets (10~{super 3}/uL)	211	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Platelets (10~{super 3}/uL)	213	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	**Vaccination Group**	**Sex**	**Age (years)**	**Planned Study Day**	**Actual Study Day**	**Laboratory Parameter (Units)**	**Result (Severity)**	**Relationship to Vaccination**	**If Not Related, Alternative Etiology**	**Action Taken with Study Vaccination**	**Subject Discontinued Due to Result?**
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	72	-1	-20	WBC (10~{super 3}/uL)	6.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	1	1	WBC (10~{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	72	8	8	WBC (10~{super 3}/uL)	5.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Aspartate Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	PT (seconds)	9.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Platelets (10~{super 3}/uL)	144	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Platelets (10~{super 3}/uL)	104 (Moderate)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Platelets (10~{super 3}/uL)	125 (Mild)	RELATED	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E *(continued)*
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	-1	-18	WBC (10~{super 3}/uL)	6.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	1	1	WBC (10~{super 3}/uL)	5.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (≥71 years)	MALE	71	8	8	WBC (10~{super 3}/uL)	6.5	N/A	N/A	N/A	N/A

APPENDIX F:
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
[redacted] (b) (6)	250 mcg mRNA-1273 (18-55 years)	-1	-21	37.2	121	85	80	79.9	184.5
[redacted]	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	66	81	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	8	8	36.4	108	73	76	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	15	15	36.2	120	82	82	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	29	29	36.3	123	76	82	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	36	36	36.1	114	77	71	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	115	80	64	84.4	175.5
[redacted]	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	110	76	64	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	8	7	36.4	130	82	79	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	130	82	102 (Mild)	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	128	80	73	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	36	35	36.6	119	82	75	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	43	42	36.3	121	79	80	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	57	55	37.1	126	83	63	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.1	137	98 (Moderate)	78	68.8	169.4
	100 mcg mRNA-1273 (18-55 years)	1	1	36.4	138	90	73	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	37.2	138	80	78	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	137	90	67	.	.
	100 mcg mRNA-1273 (18-55 years)	29	28	36.9	133	87	92	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	136	89	82	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	37.1	133	84	78	.	.
	100 mcg mRNA-1273 (18-55 years)	57	56	37.1	129	84	86	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	130	83	63	93	181.7
	100 mcg mRNA-1273 (18-55 years)	1	1	37	128	81	76	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.8	117	75	68	.	.
	100 mcg mRNA-1273 (18-55 years)	15	13	37.2	117	81	73	.	.
	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	134	89	68	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	36	34	36.4	109	71	62	.	.
	100 mcg mRNA-1273 (18-55 years)	43	40	36.9	100	66	78	.	.
	100 mcg mRNA-1273 (18-55 years)	57	55	36.3	111	75	76	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	106	68	51 (Mild)	73.5	172
	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	129	74	55	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.9	122	72	85	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	120	74	55	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	118	78	58	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	36.8	117	69	82	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	108	76	53 (Mild)	.	.
	100 mcg mRNA-1273 (18-55 years)	57	55	36.2	113	70	57	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	116	77	53 (Mild)	69.7	160.7
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	78	53 (Mild)	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	37.1	101	67	56	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	15	13	37.1	109	67	91	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.3	106	76	83	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37.6	107	66	80	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	36.9	110	74	96	.	.
	100 mcg mRNA-1273 (18-55 years)	57	56	36.9	108	74	66	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.9	137	81	63	76.1	170
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	111	71	63	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	105	65	59	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	36.7	111	73	63	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	118	69	73	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	37	119	66	64	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	77	74	.	.
	100 mcg mRNA-1273 (18-55 years)	57	57	36.3	114	69	76	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-20	37.3	115	73	76	55.7	157.5

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	37.2	120	78	66	.	.
	250 mcg mRNA-1273 (18-55 years)	8	7	37.3	107	74	74	.	.
	250 mcg mRNA-1273 (18-55 years)	15	16	37.4	111	76	75	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	36.8	104	77	75	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	37	105	71	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-10	36.8	127	86	55	95.9	181.7
	250 mcg mRNA-1273 (18-55 years)	1	1	36.2	124	89	58	.	.
	250 mcg mRNA-1273 (18-55 years)	8	7	37.1	122	87	60	.	.
	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	121	82	72	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	130	87	68	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.5	114	86	72	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.2	150 (Mild)	85	69	81.5	177
	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	82	71	.	.
	100 mcg mRNA-1273 (56-70 years)	8	7	36.6	145 (Mild)	79	69	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	**Vaccination Group**	**Planned Study Day**	**Actual Study Day**	**Temperature (ºC)**	**Systolic Blood Pressure (mmHg)**	**Diastolic Blood Pressure (mmHg)**	**Heart Rate (beats/min)**	**Weight (kg)**	**Height (cm)**
(b) (6)	100 mcg mRNA-1273 (56-70 years)	15	14	36.4	139	83	68	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	130	83	63	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	122	79	83	83.3	174.5
	100 mcg mRNA-1273 (56-70 years)	1	1	36.3	120	75	99	.	.
	100 mcg mRNA-1273 (56-70 years)	8	9	36.4	123	77	82	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.5	109	76	94	.	.
	100 mcg mRNA-1273 (56-70 years)	29	30	36.4	112	67	96	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	37.3	136	81	80	72.2	158.1
	25 mcg mRNA-1273 (56-70 years)	1	1	37.2	113	77	82	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	37.2	128	71	80	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.2	132	71	78	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.6	119	73	79	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	138	78	56	64.7	166.5
	25 mcg mRNA-1273 (56-70 years)	1	1	36.3	109	66	66	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	111	69	70	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.3	92	53	63	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	102	60	62	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	138	84	81	52	149
	25 mcg mRNA-1273 (56-70 years)	1	1	37	140	86	78	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	134	80	86	.	.
	25 mcg mRNA-1273 (56-70 years)	15	16	36.1	134	78	80	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	37	113	72	70	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	115	72	41 (Severe)	88.6	186
	25 mcg mRNA-1273 (56-70 years)	1	1	37	143 (Mild)	79	74	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	122	74	68	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	102	55	61	.	.
	25 mcg mRNA-1273 (56-70 years)	29	30	36.3	116	69	61	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.7	110	72	78	56.4	164.5

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	101	71	89	.	.
	100 mcg mRNA-1273 (56-70 years)	8	7	37.3	113	70	88	.	.
	100 mcg mRNA-1273 (56-70 years)	15	14	37.2	109	75	86	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	37.1	110	75	90	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	147 (Mild)	93 (Mild)	75	64.2	160.1
	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	93 (Mild)	75	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	36.1	142 (Mild)	89	83	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.4	142 (Mild)	92 (Mild)	85	.	.
	100 mcg mRNA-1273 (56-70 years)	29	29	36.3	146 (Mild)	91 (Mild)	72	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	37.2	134	87	60	66.5	171
	100 mcg mRNA-1273 (56-70 years)	1	1	36.4	130	84	66	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	37	120	79	71	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	116	78	77	.	.
	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	126	88	75	.	.

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	-1	-2	36.4	121	79	58	62	163.1
	25 mcg mRNA-1273 (56-70 years)	1	1	37.1	113	71	72	.	.
	25 mcg mRNA-1273 (56-70 years)	8	9	36.3	104	64	62	.	.
	25 mcg mRNA-1273 (56-70 years)	15	16	36.4	113	68	63	.	.
	25 mcg mRNA-1273 (56-70 years)	29	30	36.8	124	69	61	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.3	129	74	53 (Mild)	60.6	167.7
	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	129	81	62	.	.
	100 mcg mRNA-1273 (56-70 years)	8	7	36.5	116	70	65	.	.
	100 mcg mRNA-1273 (56-70 years)	15	14	36.9	113	71	64	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	37.4	128	72	67	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	122	77	77	78.5	167.9
	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	119	58	70	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	126	73	85	.	.
	100 mcg mRNA-1273 (18-55 years)	15	13	36.7	112	68	80	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	113	79	91	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	118	67	73	.	.
	100 mcg mRNA-1273 (18-55 years)	43	41	36.9	117	68	86	.	.
	100 mcg mRNA-1273 (18-55 years)	57	55	36.8	125	72	98	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	129	71	67	98.7	188
	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	136	75	81	.	.
	100 mcg mRNA-1273 (18-55 years)	8	9	36.7	137	73	83	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	116	73	83	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	125	74	75	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	119	74	81	.	.
	100 mcg mRNA-1273 (18-55 years)	43	46					.	.
	100 mcg mRNA-1273 (18-55 years)	57	55					.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	140	92 (Mild)	85	81.6	172.7
	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	138	83	85	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	136	84	85	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	15	15	37	138	90	86	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	29	29	36.7	123	87	68	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	36	36	37.1	136	87	84	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	43	43	36.8	129	77	70	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	57	57	36.9	139	81	94	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	-1	-2	36.7	142 (Mild)	70	78	77.1	177.8
[redacted]	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	120	77	88	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	129	68	80	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	15	14	36.7	113	76	70	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	29	28	36.7	125	80	80	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	140	71	91	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	124	77	72	.	.
[redacted]	100 mcg mRNA-1273 (18-55 years)	57	56	36.6	126	79	70	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	-1	-4	36.4	119	83	56	87	172.7
	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	117	82	69	.	.
	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	110	76	63	.	.
	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	111	64	55	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.4	107	68	55	.	.
	100 mcg mRNA-1273 (18-55 years)	36	36	36.5	110	67	56	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	109	77	60	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.4	109	70	66	64.5	165.1
	250 mcg mRNA-1273 (18-55 years)	1	1	36.5	106	52	66	.	.
	250 mcg mRNA-1273 (18-55 years)	8	7	36.3	147 (Mild)	86	80	.	.
	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	108	60	76	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.6	115	72	69	.	.
	250 mcg mRNA-1273 (18-55 years)	36	36	36.7	114	61	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.7	103	58	58	70.6	154.9

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	118	57	68	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	104	56	59	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.7	100	67	74	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	112	58	61	.	.
	250 mcg mRNA-1273 (18-55 years)	36	36	36.8	113	56	61	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-13	36.8	116	71	68	74.1	162.6
	250 mcg mRNA-1273 (18-55 years)	1	1	36.9	117	62	76	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	37.2	110	63	79	.	.
	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	112	69	85	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	112	61	73	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	112	65	70	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.9	115	67	69	82.9	167.6
	25 mcg mRNA-1273 (56-70 years)	1	1	36.8	100	58	79	.	.
	25 mcg mRNA-1273 (56-70 years)	8	7	36.8	112	61	75	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	25 mcg mRNA-1273 (56-70 years)	.	9	36.7	119	71	77	.	.
	25 mcg mRNA-1273 (56-70 years)	15	14	36.9	114	69	70	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	111	68	72	.	.
	25 mcg mRNA-1273 (56-70 years)	36	35	36.8	115	56	62	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.8	142 (Mild)	72	66	67.8	167.6
	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	118	64	75	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	37.1	138	70	65	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	37	123	61	69	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	118	59	70	.	.
	25 mcg mRNA-1273 (56-70 years)	36	36	36.7	129	65	70	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.6	124	78	59	71.1	167.6
	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	120	84	61	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	36.6	140	78	76	.	.
	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	139	80	60	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	132	79	57	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	140	80	85	89.8	180.3
	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	150 (Mild)	76	68	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	140	78	88	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.7	110	75	68	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	141 (Mild)	87	97	.	.
	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.6	150 (Mild)	92 (Mild)	68	68.7	175.3
	25 mcg mRNA-1273 (56-70 years)	1	1	36.6	146 (Mild)	92 (Mild)	64	.	.
	25 mcg mRNA-1273 (56-70 years)	8	8	36.5	148 (Mild)	80	69	.	.
	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	140	85	72	.	.
	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	130	92 (Mild)	68	.	.
	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	134	90	60	50.5	152.4
	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	140	92 (Mild)	69	.	.
	100 mcg mRNA-1273 (56-70 years)	8	8	37	139	68	79	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	153 (Moderate)	87	73	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	29	30	36.8	130	70	84	.	.
[redacted]	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	116	72	68	86	182.9
[redacted]	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	114	73	69	.	.
[redacted]	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	115	62	76	.	.
[redacted]	25 mcg mRNA-1273 (56-70 years)	15	15	36.9	117	69	77	.	.
[redacted]	25 mcg mRNA-1273 (56-70 years)	29	29	36.9	127	77	72	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.7	101	58	58	64.7	171.5
[redacted]	100 mcg mRNA-1273 (56-70 years)	1	1	36.8	96	60	64	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	8	8	36.9	91	63	69	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	103	57	69	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	29	29	36.8	105	70	61	.	.
[redacted]	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	141 (Mild)	70	74	95.2	195.6
[redacted]	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	129	74	75	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	**Vaccination Group**	**Planned Study Day**	**Actual Study Day**	**Temperature (ºC)**	**Systolic Blood Pressure (mmHg)**	**Diastolic Blood Pressure (mmHg)**	**Heart Rate (beats/min)**	**Weight (kg)**	**Height (cm)**
(b) (6)	100 mcg mRNA-1273 (56-70 years)	8	9	36.2	130	79	81	.	.
	100 mcg mRNA-1273 (56-70 years)	15	14	36.6	137	71	76	.	.
	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	128	84	78	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	144 (Mild)	88	75	92.7	185.7
	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	132	88	77	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	37.3	122	80	60	.	.
	25 mcg mRNA-1273 (18-55 years)	15	16	36.9	130	76	88	.	.
	25 mcg mRNA-1273 (18-55 years)	29	30	36.8	142 (Mild)	80	72	.	.
	25 mcg mRNA-1273 (18-55 years)	36	38	36.9	128	82	62	.	.
	25 mcg mRNA-1273 (18-55 years)	43	44	36.6	130	84	64	.	.
	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	120	80	80	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	106	74	65	56.2	158.7
	25 mcg mRNA-1273 (18-55 years)	1	1	37.1	104	65	72	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	37.2	101	64	88	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	**Vaccination Group**	**Planned Study Day**	**Actual Study Day**	**Temperature (ºC)**	**Systolic Blood Pressure (mmHg)**	**Diastolic Blood Pressure (mmHg)**	**Heart Rate (beats/min)**	**Weight (kg)**	**Height (cm)**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	15	15	36.8	114	69	99	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	29	30	37.1	102	67	84	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	113	79	89	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	43	44	36.9	103	58	86	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	57	59	37	111	72	83	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	114	69	56	62.9	172.6
[redacted]	25 mcg mRNA-1273 (18-55 years)	1	1	37	120	63	56	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	8	8	36.7	111	65	67	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	15	15	36.7	112	63	65	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	29	30	37	106	56	58	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	118	61	57	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	43	44	36.7	108	53	62	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	57	59	36.6	114	64	65	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	105	65	80	57.8	164.6

Appendix F *(continued)*
Vital Signs Listing

Subject ID	**Vaccination Group**	**Planned Study Day**	**Actual Study Day**	**Temperature (ºC)**	**Systolic Blood Pressure (mmHg)**	**Diastolic Blood Pressure (mmHg)**	**Heart Rate (beats/min)**	**Weight (kg)**	**Height (cm)**
(b) (6)	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	128	61	87	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8	36.4	113	57	82	.	.
	25 mcg mRNA-1273 (18-55 years)	15	15	36.6	103	65	69	.	.
	25 mcg mRNA-1273 (18-55 years)	29	30	36.9	114	59	77	.	.
	25 mcg mRNA-1273 (18-55 years)	36	38	36.4	115	52	76	.	.
	25 mcg mRNA-1273 (18-55 years)	43	44	37.1	109	52	81	.	.
	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	100	66	78	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.7	139	97 (Moderate)	73	83.4	162.6
	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	137	80	94	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	37	122	79	64	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	131	83	68	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	133	76	82	.	.
	100 mcg mRNA-1273 (18-55 years)	36	35	37	127	79	70	.	.
	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	125	71	64	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	57	59	36.6	122	84	68	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.8	103	55	73	54.2	163.1
	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	103	55	70	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.9	105	52	67	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37	101	62	68	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	97	54	65	.	.
	100 mcg mRNA-1273 (18-55 years)	36	37	36.8	115	64	68	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	36.9	96	54	79	.	.
	100 mcg mRNA-1273 (18-55 years)	57	59	36.9	108	56	76	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.5	117	61	61	72.2	166.1
	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	103	61	66	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	110	68	60	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.6	108	70	67	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.4	109	71	69	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	36	37	36.3	102	59	63	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	105	59	73	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	111	72	66	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.3	121	70	61	107.9	182
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	128	73	89	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	112	74	96	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	116	68	69	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	150 (Mild)	69	81	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	112	64	75	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.7	116	64	72	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	115	68	81	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.4	139	66	55	81.6	169.2
	100 mcg mRNA-1273 (18-55 years)	1	1	37.2	138	71	72	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	37.1	130	65	68	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	118	60	69	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	120	61	70	.	.
	100 mcg mRNA-1273 (18-55 years)	36	37	37.1	117	56	68	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	114	72	80	.	.
	100 mcg mRNA-1273 (18-55 years)	57	58	37.2	109	52	73	.	.
	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.8	114	69	84	72.5	166.6
	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	116	67	87	.	.
	100 mcg mRNA-1273 (18-55 years)	8	7	36.7	112	63	93	.	.
	100 mcg mRNA-1273 (18-55 years)	15	14	37	114	67	88	.	.
	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	94	50	81	.	.
	100 mcg mRNA-1273 (18-55 years)	36	37	37.4	119	55	94	.	.
	100 mcg mRNA-1273 (18-55 years)	43	43	37	113	61	97	.	.
	100 mcg mRNA-1273 (18-55 years)	57	58	37.3	96	52	73	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-13	36.5	110	70	63	76.6	173.7

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	1	1	37.2	101	62	79	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	37	105	65	66	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.8	110	72	81	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	107	64	68	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.5	106	62	67	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	37	115	68	73	.	.
	25 mcg mRNA-1273 (18-55 years)	57	58	36.8	102	61	81	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-12	36.5	115	70	64	88.3	182.1
	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	114	65	57	.	.
	25 mcg mRNA-1273 (18-55 years)	8	8					.	.
	25 mcg mRNA-1273 (18-55 years)	15	17	36.7	133	76	62	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	125	69	56	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.6	114	65	55	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.9	126	61	55	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	**Vaccination Group**	**Planned Study Day**	**Actual Study Day**	**Temperature (ºC)**	**Systolic Blood Pressure (mmHg)**	**Diastolic Blood Pressure (mmHg)**	**Heart Rate (beats/min)**	**Weight (kg)**	**Height (cm)**
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	118	67	65	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	115	59	62	72.8	182.9
[redacted]	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	110	58	60	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	113	73	73	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	104	60	68	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	29	29	36.9	115	57	72	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	36	37	36.4	116	53	82	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	43	45	36.4	117	68	73	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	114	65	70	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.8	107	72	77	91.5	174.2
[redacted]	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	111	72	81	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	121	85	95	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	117	71	75	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	115	71	73	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	36	36	36.6	118	73	84	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	125	76	98	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	114	71	93	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	106	67	84	65.9	174.5
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	80	82	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	107	70	97	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	37.6	110	67	80	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	104	64	78	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	37.1	111	71	79	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	100	58	91	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	37.1	111	71	93	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.3	129	79	75	71.5	177.4
	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	131	79	78	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	123	76	77	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	115	72	74	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	108	62	83	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	106	59	81	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	117	72	83	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	113	68	76	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.2	105	64	72	69.2	167.4
[redacted]	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	104	55	72	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	8	9	36.7	110	65	85	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	15	14	37.1	108	66	80	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	99	58	70	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	110	60	78	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	110	60	84	.	.
[redacted]	25 mcg mRNA-1273 (18-55 years)	57	58	36.6	118	57	79	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	142 (Mild)	82	56	76.7	185.7

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	133	69	90	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.7	132	60	63	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	37	128	68	62	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	36.4	125	75	63	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.8	120	64	65	.	.
	250 mcg mRNA-1273 (18-55 years)	43	43	36.3	122	71	67	.	.
	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	131	72	72	68.8	179.5
	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	69	69	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	116	70	79	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	37	104	58	71	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	37.1	104	58	78	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	123	69	92	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	120	79	86	.	.
	25 mcg mRNA-1273 (18-55 years)	57	56	36.7	110	73	80	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	25 mcg mRNA-1273 (18-55 years)	-1	-7	36.6	132	74	98	92.3	194.1
	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	129	73	69	.	.
	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	122	67	71	.	.
	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	109	64	66	.	.
	25 mcg mRNA-1273 (18-55 years)	29	29	36.6	116	62	75	.	.
	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	119	55	79	.	.
	25 mcg mRNA-1273 (18-55 years)	43	45	36.5	114	68	72	.	.
	25 mcg mRNA-1273 (18-55 years)	57	57	37.1	121	59	79	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-21	36.9	107	56	72	53	161
	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	116	72	70	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	111	75	70	.	.
	250 mcg mRNA-1273 (18-55 years)	15	16	36.6	116	72	77	.	.
	250 mcg mRNA-1273 (18-55 years)	29	28	36.5	117	76	68	.	.
	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	110	69	82	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	250 mcg mRNA-1273 (18-55 years)	43	43	36.6	122	68	95	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	136	96 (Moderate)	87	81.1	173.2
[redacted]	250 mcg mRNA-1273 (18-55 years)	1	1	37	133	85	87	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	138	91 (Mild)	56	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	138	83	64	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	29	29	37.7	137	83	84	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	36	36	37.2	130	84	75	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	-1	-20	37	120	62	90	53.2	159.8
[redacted]	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	114	62	88	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	118	72	88	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	15	16	36.5	131	72	89	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	29	28					.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	111	55	84	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	43	43	36.7	122	72	82	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	-1	-19	37	127	66	77	75.6	176.2
[redacted]	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	120	69	99	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	131	75	90	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	15	16	37.1	116	67	86	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	130	65	83	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	129	67	74	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	75	71	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	-1	-24	36.9	142 (Mild)	85	53 (Mild)	80.1	167
[redacted]	250 mcg mRNA-1273 (18-55 years)	1	1	37	124	68	75	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	131	75	74	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	109	71	62	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	29	29	37.1	126	73	62	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	137	81	65	.	.
[redacted]	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.7	136	82	71	83.9	179.3

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	139	86	72	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	37.1	139	82	69	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	131	74	71	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	118	66	77	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	37.3	124	76	71	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.4	102	61	65	52.1	152.7
	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	98	54	63	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	94	52	67	.	.
	250 mcg mRNA-1273 (18-55 years)	15	15	36.4	98	53	52 (Mild)	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.7	85 (Mild)	49	55	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	36.5	85 (Mild)	49	61	.	.
	250 mcg mRNA-1273 (18-55 years)	-1	-20	36.9	114	55	71	55.1	157.7
	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	107	63	68	.	.
	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	114	65	66	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	**Vaccination Group**	**Planned Study Day**	**Actual Study Day**	**Temperature (ºC)**	**Systolic Blood Pressure (mmHg)**	**Diastolic Blood Pressure (mmHg)**	**Heart Rate (beats/min)**	**Weight (kg)**	**Height (cm)**
(b) (6)	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	113	65	83	.	.
	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	116	61	77	.	.
	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	105	59	75	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.7	109	69	76	87.6	173.2
	25 mcg mRNA-1273 (≥71 years)	1	1	36.7	110	68	81	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.7	112	78	72	.	.
	25 mcg mRNA-1273 (≥71 years)	15	15	36.5	120	78	65	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.9	131	60	58	47.4	153.9
	25 mcg mRNA-1273 (≥71 years)	1	1	36.3	145 (Mild)	70	57	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	149 (Mild)	68	53 (Mild)	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	140	70	58	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	122	77	71	84	179
	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	128	77	74	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.8	112	72	73	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	113	68	71	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	143 (Mild)	66	75	62.5	171.7
	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	141 (Mild)	76	68	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	129	68	70	.	.
	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	140	76	67	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-13	37.1	112	73	74	83.5	174.9
	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	136	79	72	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	130	84	80	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.9	134	75	78	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-21	36.4	121	69	55	83.7	169.1
	100 mcg mRNA-1273 (≥71 years)	1	1	36.8	109	57	62	.	.
	100 mcg mRNA-1273 (≥71 years)	8	9	36.6	115	55	62	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.9	126	84	77	78.3	171.1
	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	148 (Mild)	92 (Mild)	62	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	128	87	89	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	136	85	94	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.8	124	65	86	73.8	180.1
	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	135	81	82	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.5	124	66	75	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	120	74	71	.	.
	100 mcg mRNA-1273 (≥71 years)	-1	-14	36.9	112	56	78	67.4	152.5
	100 mcg mRNA-1273 (≥71 years)	1	1	36.4	122	58	66	.	.
	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	103	54	65	.	.
	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	109	67	71	.	.
	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.1	117	68	71	53.3	163.6
	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	120	69	68	.	.
	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	128	73	69	.	.
	25 mcg mRNA-1273 (≥71 years)	15	16	36.4	122	68	65	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.2	125	68	74	78.3	164.6
[redacted]	25 mcg mRNA-1273 (≥71 years)	1	1	37	139	63	79	.	.
[redacted]	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	117	62	63	.	.
[redacted]	25 mcg mRNA-1273 (≥71 years)	15	16	36.8	114	59	77	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-20	36.9	143 (Mild)	78	73	60.7	156.9
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	37.3	145 (Mild)	75	72	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	37	148 (Mild)	75	73	.	.
[redacted]	25 mcg mRNA-1273 (≥71 years)	-1	-12	36.7	146 (Mild)	70	53 (Mild)	80.8	178.2
[redacted]	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	119	64	62	.	.
[redacted]	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	136	66	56	.	.
[redacted]	25 mcg mRNA-1273 (≥71 years)	15	15	36.9	129	71	58	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-12	36.8	122	67	68	68.4	162.8
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	36.5	117	58	72	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	128	69	65	.	.

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	129	62	61	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-18	36.7	114	56	74	78.7	162.8
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	118	56	74	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	137	60	83	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.6	133	74	63	91.2	181.7
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	136	67	59	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	37.2	134	78	73	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.9	118	53	63	57.9	169.6
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	116	54	64	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	139	60	63	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-18	37.1	118	58	57	62.4	171
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	113	75	65	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	127	60	54 (Mild)	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.8	134	65	69	71.2	173.9

Appendix F *(continued)*
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (ºC)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
(b) (6) [redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	119	58	60	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	36.8	132	70	57	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	-1	-17	37.2	144 (Mild)	83	78	80	165.4
[redacted]	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	132	71	75	.	.
[redacted]	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	142 (Mild)	74	78	.	.

APPENDIX G1:
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Subject unable to comply	No	No	No	subject instructed to eat and hydrate well before clinic visit	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Subject unable to comply	No	No	No	Not enough blood sample after multiple sticks. Subject will be advised to hydrate more.	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Laboratory error	No	No	No	Rinse more CPT tubes to collect buffy coat layer	Suspected that the entire buffy coat wasn't collected

Appendix G1 *(continued)*
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	3	Too few aliquots obtained	Protocol procedure/assessment	34	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	55	Clinic error	No	No	No	Remind staff to double check the amount of blood collected.	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Laboratory error	No	No	No	Rinse more CPT tubes to collect buffy coat layer	Suspected that entire buffy coat wasn't collected

Appendix G1 *(continued)*
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: poor quality PBMC layer	No	No	No	Deviation not due to human error	
	25 mcg mRNA-1273 (56-70 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	Other: Poor quality PBMC layer	No	No	No	Deviation not due to human error	
	100 mcg mRNA-1273 (56-70 years)	1	Missed visit/visit not conducted	Follow-up visit schedule	2	Subject unable to comply	No	No	No	Explained the importance of completing study visits to the subject	Once contact was made with the subject, the importance of completing each study visit within the time frame was reiterated and subject responded with an understanding.
	100 mcg mRNA-1273 (18-55 years)	1	Out of window visit	Follow-up visit schedule	46	Subject refusal	No	No	No	subjects will be reminded of importance of attending study visits within window	

Appendix G1 *(continued)*
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	46	Subject refusal	No	No	No	subject moved out of state unexpectedly	
[redacted]	100 mcg mRNA-1273 (18-55 years)	3	Required procedure done incorrectly	Protocol procedure/assessment	55	Subject refusal	No	No	No	subject moved out of state unexpectedly	
[redacted]	250 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	7	Clinic error	Yes, unsolicited AE	No	No	Coordinator re-trained on the importance of preforming required procedures	
[redacted]	25 mcg mRNA-1273 (18-55 years)	1	Other: non-required lab tests performed	Protocol procedure/assessment	1	Laboratory error	No	No	N/A	staff instructed to review study requirements and lab form prior to submission	lab staff did not fill out requisition form properly, so complete CBC was done rather than only study required tests.

Appendix G1 *(continued)*
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	25 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	-14	Laboratory error	No	No	No	Lab staff will prepare tubes prior to study visit and double -check tubes again post-draw	Incorrect tube size was used during specimen collection. As a preventative measure, lab staff will prepare blood collection tubes prior to study visits and double-check again post-draw to confirm correct tubes were used.
	100 mcg mRNA-1273 (18-55 years)	1	Other: breach of confidentiality	Protocol procedure/assessment	-4	Clinic error	No	No	N/A	retraining of study staff	subject name was included on Quest requisition form, rather than study ID.
	25 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	8	Investigator/study decision	No	No	N/A	Pt. under quarantine due to exposure, required procedures will be completed at V5	

Appendix G1 *(continued)*
Listing of Protocol Deviations

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
(b) (6)	25 mcg mRNA-1273 (18-55 years)	2	Other: V4 safety labs collected out of window	Protocol procedure/assessment	17	Subject unable to comply	No	No	N/A	Pt. unable to comply due to quarantine. V4 safety labs drawn at V5	
	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Treatment administration schedule	28	Subject illness	No	No	No	Will continue to attempt to complete visits per protocol	
	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	1	Laboratory error	No	No	N/A	Lab staff will use a timer for visits requiring safety labs due to their shorter clot time window.	

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

APPENDIX G2:
Listing of Non-Subject Deviations

Study Site	Deviation Number	Deviation	Deviation Category	Reason for Deviation	Deviation Affected Product Stability?	Deviation Resolution	Comments
Emory Children's Center	1	Study product temperature excursion: EUC -80 freezer was out of range on April 17, 2020	Protocol procedure/assessment	Other:EUC -80 freezer had a malfunction.	Yes	A new -80 freezer has been purchased and in use.	The affected study product was immediately removed from EUC -80 freezer to EUH -80 freezer on April 17, 2020. The excursion was reported to DMID on April 18, 2020. DMID instructed to continue to use IP.

APPENDIX H:
Listing of Pregnancies

Table 1 – Maternal Information

No maternal information has been reported

Table 2 – Gravida and Para

No gravida and para have been reported.

Table 3 – Live Birth Outcomes

No live birth outcomes have been reported

Table 4 – Still Birth Outcomes

No maternal information has been reported

Table 5 – Spontaneous, Elective, or Therapeutic Abortion Outcomes

No spontaneous, elective, or therapeutic abortion outcomes have been reported